BioTuesdays

Category - Features

In conversation with Pivotal Therapeutics

BioTuesdays.com recently sat down with the management team at Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to discuss the company’s VASCAZEN product that addresses Omega-3 deficiency in cardiovascular disease (CVD)...

Finding the origins of cancer with Rosetta Genomics

Taking its name from the Rosetta Stone, which paved the way to decipher ancient Egyptian hieroglyphics, Rosetta Genomics (NASDAQ:ROSG) is unlocking the relevance of microRNA within the human genome to develop next...

Titan implanting treatments for opioid dependence

In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a matchstick-sized...

In conversation with Jason Mitakidis

As president and CEO of closely held Cyclica, Jason Mitakidis first became interested in computer simulation or, in silico, drug discovery while he was working as a bioinformatician at the Barcode of Life...

XTL hopes to begin major lupus trial next year

XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). “We are in the...

Medifocus readies marketing expansion of Prolieve

Medifocus (OTCQX:MDFZF; TSX-V:MFS) is raising $6-million to $10-million to expand the sales and marketing of its minimally invasive Prolieve device as a treatment for benign prostatic hyperplasia (BPH), or enlarged...

Response Biomedical charting turnaround story

The new management team of Response Biomedical (OTCBB:RPBIF; TSX:RBM), with the strong support of its controlling shareholder, OrbiMed Advisors, has adopted an aggressive plan to drive sales and achieve profitability...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.